Compare Alcon AG (ALC) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs iShares Core MSCI EAFE ETF — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while iShares Core MSCI EAFE ETF trades at $96.31. The key difference: Alcon AG pays a 0.54% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | IEFA | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $92.22 | $98.56 |
52-Week Low | $62.02 | $81.70 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
IEFA trades at $98.31, up 1.04% with a bullish technical signal from moving averages. The ETF focuses on developed international markets excluding North America, offering diversification from US concentration risks. Recent news highlights strong performance comparisons against peers like VXUS and EEM, with a competitive 3.30% dividend yield and low 0.07% expense ratio. Central bank policy shifts in Europe and Japan present both opportunities and headwinds for international exposure.
The outlook remains positive given technical momentum and diversification benefits, though currency fluctuations and developed market monetary policy changes pose risks. Analyst sentiment leans bullish with the ETF positioned as a core holding for international diversification, but investors should monitor geopolitical developments and relative performance against US equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
